SCHEMBL719225

SCHEMBL719225

COC(=O)c1ccc(NC(c2sc3cccnc3c2C)C2CCCCC2)cc1

nearest known ligand 0.48

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RCE1 Q9Y256 1/20 0.48
ALDH1A1 P00352 5/20 0.41
NPC1 O15118 3/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
EPHX2 P34913 1/20 0.41
EGLN1 Q9GZT9 1/20 0.40
CYP2C19 P33261 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
NPSR1 Q6W5P4 1/20 0.36
RAB9A P51151 2/20 0.36
PDE10A Q9Y233 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
EPHX1 P07099 1/20 0.35
PDE7A Q13946 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL719453 0.90 RCE1 (0.60) RCE1ALDH1A1NPC1CYP2C19CYP1A2
SCHEMBL14905674 0.86 RCE1 (0.44) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2
SCHEMBL720271 0.84 ALDH1A1 (0.41) ALDH1A1NPC1SMN1; SMN2EPHX2CYP2C19
SCHEMBL3402636 0.83 GCG (0.48) RCE1SMN1; SMN2
SCHEMBL3403776 0.82 RCE1 (0.45) RCE1MEN1KMT2APDE7A
SCHEMBL719072 0.82 MEN1 (0.42) RCE1SMN1; SMN2MEN1KMT2APDE7A
SCHEMBL720172 0.82 ALDH1A1 (0.44) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2
SCHEMBL10284811 0.81 RCE1 (0.42) RCE1EPHX2MEN1KMT2APDE7A
SCHEMBL719238 0.81 RCE1 (0.41) RCE1NPC1MEN1KMT2APDE7A
SCHEMBL717537 0.80 RCE1 (0.48) RCE1ALDH1A1NPC1SMN1; SMN2EPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RCE1 2661/4885ALDH1A1 504/4885NPC1 902/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP RCE1 2661/4885ALDH1A1 504/4885NPC1 902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.